Atlas Venture, a leading early stage venture capital and venture creation firm investing in biotech innovation, today announced the closing of its second Opportunity Fund, raising $300 million in an oversubscribed fundraise. Atlas Venture Opportunity Fund II (AVOF II), will enable Atlas to continue its model of supporting its portfolio companies as they raise subsequent financings and advance therapeutic programs.
October 1, 2021 | Press Release
Atlas Venture Announces $300 Million Second Opportunity Fund
August 31, 2021 | In the News
Atlas, Medicxi Invest $70M in Antibody for Obesity Licensed from Novartis
Science and industry have been working, for what seems like a lifetime, to come up with a safe and effective treatment for obesity.
August 27, 2021 | From the Trenches
In the Shadows
I recently stepped down after a six-year stint as Chairman of uniQure (NASDAQ: QURE). In the process of interviewing potential successors, one candidate observed that “there is no manual for how to chair a biotech company.” I had never really thought about that previously, but the comment struck a chord. While I am not sure I have it in me to write a manual, a blog seemed a manageable and appropriate means to share a few learnings from my experience serving as chair of four companies (two public and two private) and working with six chairs or lead independent directors in three CEO / President roles over the past two decades.
By Philip Astley-Sparke, CEO of Replimune, as part of the From The Trenches feature of LifeSciVC.
August 18, 2021 | In the News
Vigil bags $90M to take ex-Amgen assets on path from rare diseases to Alzheimer’s
Vigil Neuroscience is barreling forward with a strategy that will see it hop along steppingstones from rare diseases to Alzheimer’s. Having emerged with $50 million late last year, Vigil has gathered up an additional $90 million to validate its ex-Amgen asset in a rare, inherited neurodegenerative disease.
August 16, 2021 | From the Trenches
Mind Your Manners: Best Practices and Basic Etiquette in Business Development
It’s tempting to think that the first skill you need to learn in business development is negotiating. That’s important, of course, but it should not be your first stop. Business development, at its core, is all about building relationships. And while that may sound simple, I’ve seen many up-and-comers stumble because they fail to understand best practices and basic etiquette at the foundation of strong business relationships.
By Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC